ocaratuzumab

Known as: MoAb CD20, monoclonal antibody CD20, monoclonal antibody, CD20 
An Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab specifically binds to CD20… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2016
01220122016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
The anti-CD20 antibodies represent a major advancement in the therapeutic options available for chronic lymphocytic leukemia. The… (More)
Is this relevant?
2016
2016
Unconjugated monoclonal antibodies (mAbs) are an important component of effective combination therapies for chronic lymphocytic… (More)
  • figure 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2016
Review
2016
The conventional treatment for patients with pemphigus vulgaris (PV) centers on global immunosuppression, such as the use of… (More)
Is this relevant?
2015
2015
This phase 2 study assessed the safety and efficacy of ocaratuzumab, a humanized anti-CD20 monoclonal antibody. Fifty patients… (More)
Is this relevant?
Review
2015
Review
2015
INTRODUCTION Over the last few years, several new immunological drugs, particularly monoclonal antibodies (mAbs… (More)
Is this relevant?
2014
2014
Chronic lymphocytic leukemia (CLL) is common in both developed and developing nations where the need for inexpensive and… (More)
Is this relevant?
2013
2013
Copyright: © 2013 Uckun FM. This is an open-access article distributed under the terms of the Creative Commons Attribution… (More)
Is this relevant?
Review
2012
Review
2012
Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?